Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $68 from $64 and keeps an Outperform rating on the shares, which were added to the firm’s “Tactical Outperform” list. Gross margins to be flat sequentially implies volumes could beat, says the analyst, who likes the set-up into Q3 with the CRC blood test “derisked.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $65 from $55 at Barclays
- Exact Sciences added to Q4 2025 Tactical Ideas List at Wells Fargo
- Exact Sciences Receives Buy Rating from Bruce Jackson Amid Promising MCED Test Launch and Strong Financial Projections
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call
- Exact Sciences management to meet with Craig-Hallum